Metastatic Triple-Negative Breast Cancer Clinical Trial
Official title:
ToPCourT: A Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (TNBC)
The goal of this phase II study is to test the combination of trilaciclib, pembrolizumab, gemcitabine, and carboplatin in locally advanced unresectable or metastatic triple-negative breast cancer. The main questions it aims to answer are: - to evaluate the anti-cancer efficacy (assess how well it works) - to evaluate the safety and tolerability (how well the body can handle the treatment) of this combination of anti-cancer therapy
This is an open label, single-arm, phase II trial designed to evaluate the efficacy of trilaciclib, pembrolizumab, gemcitabine and carboplatin in participants with locally advanced unresectable or metastatic triple-negative breast cancer. Pembrolizumab will be given for a maximum of 2 years. Eligible participants will receive the study treatment until disease progression, unacceptable toxicity, or withdrawal for any reason. A tumor biopsy will be collected from participants in which it can be safely obtained before the first dose of treatment, prior to Cycle 3 Day 1, and at the time of disease progression (optional). Blood specimens for correlative studies will be collected pre-treatment Cycle 1 Day 1, prior to treatment Cycle 2 Day 1, prior to treatment Cycle 3 Day 1, 3 months after the start of study treatment, and 6 months after the start of study treatment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04986852 -
Olinvacimab With Pembrolizumab in Patients With mTNBC
|
Phase 2 | |
| Recruiting |
NCT05831553 -
TIP in Patients Affected by Metastatic TNBC
|
||
| Recruiting |
NCT05570253 -
A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04454437 -
Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments
|
Phase 2 | |
| Recruiting |
NCT05101096 -
Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05227664 -
A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer
|
Phase 2 | |
| Suspended |
NCT04250818 -
Predicting Response of Metastatic Triple Negative Breast Cancer to Immunotherapy Based on Patients Cytokine Profile
|
||
| Completed |
NCT03004183 -
SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC
|
Phase 2 | |
| Not yet recruiting |
NCT05746728 -
Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05089643 -
Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer
|
Phase 2 |